A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

Conditions:   Mantle Cell Lymphoma;   Mantle Cell Lymphoma Refractory Interventions:   Drug: Glofitamab;   Drug: Pirtobrutinib;   Drug: Obinutuzumab;   Drug: Tocilizumab Sponsor:   Australasian Leukaemia and Lymphoma Group Not yet recruiting

Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials